Free Trial
→ Why Buffett and 100 members of Congress are Piling into this One Investment (From Behind the Markets) (Ad)

MediciNova Q3 2023 Earnings Report

MediciNova logo
$1.83 +0.06 (+3.10%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

MediciNova EPS Results

Actual EPS
-$0.01
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

MediciNova Revenue Results

Actual Revenue
$1.00 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MediciNova Announcement Details

Quarter
Q3 2023
Date
11/9/2023
Time
N/A

Conference Call Resources

MediciNova Earnings Headlines

MediciNova (MNOV) Projected to Post Earnings on Thursday
February 18, 2025 | americanbankingnews.com
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…
December 9, 2024 | msn.com
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
February 22, 2025 | WealthPress (Ad)
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
December 5, 2024 | globenewswire.com
MediciNova Inc.
December 5, 2024 | wsj.com
D. Boral Capital Initiates Coverage of MediciNova (MNOV) with Buy Recommendation
December 3, 2024 | msn.com
See More MediciNova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email.

About MediciNova

MediciNova (NASDAQ:MNOV), a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

View MediciNova Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles